Board appointment at Ardea Biosciences
This article was originally published in Scrip
Ardea Biosciences (US) has appointed Dr Felix Baker to its board of directors. Dr Baker is a managing partner of Baker Bros. Advisors, the manager and advisor to the funds of Baker Brothers Investments, Ardea's largest shareholder. Ardea is a California-based biotech company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and HIV.
You may also be interested in...
Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.
Several newly repurposed drugs, including a Bayer antimalarial, have shown potential benefits against the new coronavirus, promoting China to add several to its latest revised treatment guidelines.
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.